[1] BIENENFELD A,AZARCHI S,SICCO K L,et al.Androgens in women:androgen-mediated skin disease and patient evaluation[J].J Am Acad Dermatol,2019,80(6):1497-1506.
[2] TAO L J,SEO D E,JACKSON B,et al.Nuclear hormone receptors and their ligands:metabolites in control of transcription[J].Cells,2020,9(12):2606.
[3] DRÉNO B,DAGNELIE M A,KHAMMARI A,et al.The skin microbiome:a new actor in inflammatory acne[J].Am J Clin Dermatol,2020,21(Suppl 1):18-24.
[4] JAISSER F,FARMAN N.Emerging roles of the mineralocorticoid receptor in pathology:toward new paradigms in clinical pharmacology[J].Pharmacol Rev,2016,68(1):49-75.
[5] AZARCHI S,BIENENFELD A,SICCO K L,et al.Androgens in women:Hormone-modulating therapies for skin disease[J].J Am Acad Dermatol,2019,80(6):1509-1521.
[6] CARONE L,OXBERRY S G,TWYCROSS R,et al.Spironolactone[J].J Pain Symptom Manage,2017,53:288-292.
[7] LAYTON A M,THIBOUTOT D,TAN J.Reviewing the global burden of acne:how could we improve care to reduce the burden?[J].Br J Dermatol,2021,184(2):219-225.
[8] KUTLU Ö,KARADAG∨ A S,WOLLINA U.Adult acne versus adolescent acne:a narrative review with a focus on epidemiology to treatment[J].An Bras Dermatol,2023,98(1):75-83.
[9] MEDINA C D E,AGUILAR M D A,ATALA F A,et al.Novedades en acné[J].Med Cutan Iber Lat Am,2019,47:7-15.
[10] GARG V,CHOI J K,JAMES W D,et al.Long-term use of spironolactone for acne in women:a case series of 403 patients[J].J Am Acad Dermatol,2021,84(5):1348-1355.
[11] BARBIERI J S,CHOI J K,MITRA N,et al.Frequency of treatment switching for spironolactone compared to oral tetracycline-class antibiotics for women with acne:a retrospective cohort study 2010—2016[J].J Drugs Dermatol,2018,17(6):632-638.
[12] REHAN S T,KHAN Z,ABBAS S,et al.Role of topical spironolactone in the treatment of acne:a systematic review of clinical trials-Does this therapy open a path towards favorable outcomes?[J].J Dermatol,2023,50(2):166-174.
[13] THIEDE R M,RASTOGI S,NARDONE B,et al.Hyperkalemia in women with acne exposed to oral spironolactone:a retrospective study from the RADAR(Research on Adverse Drug Events and Reports) program[J].Int J Womens Dermatol,2019,5(3):155-157.
[14] SCHALLER M,ALMEIDA L M C,BEWLEY A,et al.Recommendations for rosacea diagnosis,classification and management:update from the global ROSacea COnsensus 2019 panel[J].Br J Dermatol,2020,182(5):1269-1276.
[15] DEL ROSSO J Q,TANGHETTI E,WEBSTER G,et al.Update on the management of rosacea from the American Acne & Rosacea Society(AARS)[J].J Clin Aesthet Dermatol,2020,13(6 suppl):S17-S24.
[16] GOLDBURG S R,STROBER B E,PAYETTE M J.Hidradenitis suppurativa:epidemiology,clinical presentation,and pathogenesis[J].J Am Acad Dermatol,2020,82(5):1045-1058.
[17] 侯玥,刘鹏月,韩秀萍.化脓性汗腺炎的非生物制剂治疗进展[J].皮肤科学通报,2022,39(5):485-489
[18] GOLBARI N M,PORTER M L,KIMBALL A B.Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa[J].J Am Acad Dermatol,2019,80(1):114-119.
[19] LEE A,FISCHER G.A case series of 20 women with hidradenitis suppurativa treated with spironolactone[J].Australas J Dermatol,2015,56(3):192-196.
[20] HEILMANN-HEIMBACH S,HEROLD C,HOCHFELD L M,et al.Meta-analysis identifies novel risk loci and yields systematic insights into the biology of male-pattern baldness[J].Nat Commun,2017,8:14694.
[21] LIANG X,CHANG Y,WU H,et al.Efficacy and safety of 5% minoxidil alone,minoxidil plus oral spironolactone,and minoxidil plus microneedling on female pattern hair loss:a prospective,single-center,parallel-group,evaluator blinded,randomized trial[J].Front Med(Lausanne),2022,9:905140.
[22] COLLINS M S,ALI S,WISS I P,et al.Retrospective analysis of the risk of hyperkalaemia in women older than 65 years of age prescribed spironolactone for female-pattern hair loss[J].Br J Dermatol,2023,188(3):429-447.
[23] WANG C,DU Y,BI L,et al.The efficacy and safety of oral and topical spironolactone in androgenetic alopecia treatment:a systematic review[J].Clin Cosmet Investig Dermatol,2023,16:603-612.
[24] MATHESON E,BAIN J.Hirsutism in women[J].Am Fam Physician,2019,100(3):168-175.
[25] WILLIAMS T,MOORE J B,REGEHR J.Polycystic ovary syndrome:common questions and answers[J].Am Fam Physician,2023,107(3):264-272.
[26] BASHIR R,ASRAR M M,SHAH I A,et al.Do pleiotropic effects of spironolactone in women with PCOS Make it more than an anti-androgen? evidence from a systematic review and meta-analysis[J].Curr Pharm Des,2023,29(19):1486-1496.
[27] SABBADIN C,BEGGIAO F,KEIKO VEDOLIN C,et al.Long-lasting effects of spironolactone after its withdrawal in patients with hyperandrogenic skin disorders[J].Endocr Metab Immune Disord Drug Targets,2023,23(2):188-195.
[28] LEFOULON N,BEGON E,PERRISSIN-FABERT M,et al.Impact of combined oral contraceptives and spironolactone on hirsutism and quality of life[J].Gynecol Obstet Fertil Senol,2022,50(9):591-599.
[29] SEARLE T N,AL-NIAIMI F,ALI F R.Spironolactone in dermatology:uses in acne and beyond[J].Clin Exp Dermatol,2020,45(8):986-993.
[30] ROBERTS E E,NOWSHEEN S,DAVIS M D P,et al.Treatment of acne with spironolactone:a retrospective review of 395 adult patients at Mayo Clinic,2007-2017[J].J Eur Acad Dermatol Venereol,2020,34(9):2106-2110.
[31] ROBERTS E E,NOWSHEEN S,DAVIS D M R,et al.Use of spironolactone to treat acne in adolescent females[J].Pediatr Dermatol,2021,38(1):72-76.
[32] HORISSIAN M,MACZUGA S,BARBIERI J S,et al.Trends in the prescribing pattern of spironolactone for acne and hidradenitis suppurativa in adolescents[J].J Am Acad Dermatol,2022,87(3):684-686.
[33] GRABER E M.K+larity for spironolactone:at last![J].JAMA Dermatol,2015,151(9):926-927.
[34] PLANTE J,ROBINSON I,ELSTON D.The need for potassium monitoring in women on spironolactone for dermatologic conditions[J].J Am Acad Dermatol,2022,87(5):1097-1099. |
